Abstracts Archive - Page 1537 of 2425 - ACR Meeting Abstracts

Abstract Number: 1794 • 2016 ACR/ARHP Annual Meeting
The High Disease Activity State Is an Adverse Prognostic Indicator in SLE and Defines a Clinically Distinct Population
Rachel Koelmeyer¹, Eric F Morand^2,3 and Alberta Y. Hoi^2,3, ¹Centre for Inflammatory Diseases, Monash University, Clayton VIC, Australia, ²Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ³Department of Rheumatology, Monash Health, Clayton VIC, Australia
Background/Purpose: The heterogeneity of SLE in terms of disease characteristics is an issue not only for the diagnostic process but also for disease management. Previously,…
Abstract Number: 1795 • 2016 ACR/ARHP Annual Meeting
Four Years Follow-up of Subclinical Atherosclerosis in Systemic Lupus Erythematosus Patients
Ju-Yang Jung¹, Hyoun-Ah Kim¹ and Chang-Hee Suh², ¹Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ²Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, The Republic of
Background/Purpose: We assessed carotid artery intima-media thickness (cIMT) and carotid plaque by Doppler ultrasonography among sixty-one female SLE patients who were enrolled in the previous…
Abstract Number: 1796 • 2016 ACR/ARHP Annual Meeting
Osteoporosis and Vertebral Fractures in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Mario García-Carrasco^1,2, Pamela Soto-Santillan³, Samanda Adriana Rojas villarraga⁴, Nicolás Molano-González⁵ and Claudia Mendoza Pinto⁶, ¹Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Inmunología y Reumatología, Universidad Autónoma de Puebla, Puebla, Mexico, ³Internal Medicine, Systemic Autoimmune Diseases Research Unit, IMSS, Puebla, México, Puebla, Mexico, ⁴Novartis de Colombia, Bogota, Colombia, ⁵Center for Autoimmune Diseases Research (CREA). School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Bogota, Colombia, ⁶Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR, IMSS, Puebla, Mexico
Background/Purpose: Observational studies have indicated a high but heterogeneous prevalence of low bone mineral density (BMD) and vertebral fractures (FV) in patients with systemic lupus…
Abstract Number: 1797 • 2016 ACR/ARHP Annual Meeting
Seasonal Differences in the Disease Onset and the Exacerbation of Systemic Lupus Erythematosus
Takehisa Ogura¹, Ayako Hirata¹, Sayaka Takenaka², Hideki Ito², Yuki Fujisawa¹, Norihide Hayashi², Rie Kujime¹, Munetugu Imamura², Kennosuke Mizushina¹, Takaharu Katagiri² and Hideto Kameda¹, ¹Department of Rheumatology, Toho University Ohashi Medical Center, Tokyo, Japan, ²Toho University Ohashi Medical Center, Tokyo, Japan
Background/Purpose: It has been well acknowledged that both genetic and environmental factors are important in the pathogenesis of systemic lupus erythematosus (SLE). To elucidate the…
Abstract Number: 1798 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review
Sara Hussein¹, Manon Suitner¹, Alexandra Baril-Dionne¹, Mihaela Luminita Popescu¹, Nancy Santesso², Stephanie O. Keeling³, Janet E. Pope⁴, Aurore Fifi-Mah⁵ and Josiane Bourré-Tessier¹, ¹Université de Montréal, Montreal, QC, Canada, ²McMaster University, Hamilton, ON, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada
Background/Purpose: Non-traumatic osteonecrosis (ON) is a well-recognized complication in systemic lupus erythematosus (SLE). The reported symptomatic ON prevalence is 10-15% and as high as 44%…
Abstract Number: 1799 • 2016 ACR/ARHP Annual Meeting
Smoking, Antiphospholipid Antibodies and Thrombosis in SLE
Michelle Petri¹, George Stojan² and Wei Fu³, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD
Background/Purpose: Anticardiolipin Ever smoking 411 (48.1%) Past smoking 246 (49.8%) Current smoking 165 (46.6%) Never smoking 721 (48.9%) P Value (Ever vs. Never) 0.6943…
Abstract Number: 1800 • 2016 ACR/ARHP Annual Meeting
Prevalence of ECG Cardiovascular Abnormalities in Lupus Patients: A Novel Approach Using 5 ECG Elements
Hanan Al Rayes¹, Paula Harvey², Dafna D Gladman³, Arthy Sabapathy¹, Murray Urowitz¹ and Zahi Touma¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Lupus patients are at increased risk for cardiovascular disease (CVD). Chou et al. (Ann Inter Med 2011) found that resting ECG abnormalities, in particular…
Abstract Number: 1801 • 2016 ACR/ARHP Annual Meeting
Clinical Implications of Persistent Sinus Tachycardia in Systemic Lupus Erythematous: A Retrospective Study
Santosh Bhusal¹, Bassam Alhaddad², Douglas Einstadter³ and Stanley Ballou¹, ¹Rheumatology, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH, ²Rheumatology, Premier Physicians, Westlake OH, Cleveland, OH, ³Medicine, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Resting Sinus Tachycardia (ST) is found in approximately 50 % of patients with SLE. Unexplained episodes of intermittent ST could be a manifestation of…
Abstract Number: 1802 • 2016 ACR/ARHP Annual Meeting
Prevalence of CMV in the Ohio State University Lupus Population
Brian LaMoreaux¹, Alexa Meara², Holly Steigelman³, Juliette Yedimenko⁴, Wael N. Jarjour⁵ and Stacy P. Ardoin⁶, ¹Rheumatology, Fellow, Columbus, OH, ²Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ³The Ohio State University, Columbus, OH, ⁴S2056, The Ohio State University, Columbus, OH, ⁵Department of Rheumatology/Medicine, Ohio State University, Columbus, OH, ⁶Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH
Background/Purpose: Systemic Lupus Erythematous (SLE) is a clinically variable autoimmune disease occurring predominantly in women of childbearing age. SLE treatment can range from close clinical…
Abstract Number: 1803 • 2016 ACR/ARHP Annual Meeting
General Features of SLE Patients Presenting with Autoimmune Hemolytic Anemia
Regaip Elezi¹, Gulsum Emel Pamuk², Muhammet Maden², Mehmet Ali Balci^1,3 and Omer Nuri Pamuk¹, ¹Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²Hematology, Trakya University Medical Faculty, Edirne, Turkey, ³Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey
Background/Purpose: Anemia in systemic lupus erythematosus (SLE) might have various etiologies; however, autoimmune hemolytic anemia (AIHA) is the characteristic hematologic feature. AIHA might be primary…
Abstract Number: 1804 • 2016 ACR/ARHP Annual Meeting
Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: a Single Centre Experience
Konstantinos Tselios¹, Dafna D Gladman² and Murray Urowitz³, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Pulmonary arterial hypertension (PAH) is detected in 0.5-17.5% of patients with systemic lupus erythematosus (SLE). Systemic inflammation may play a dominant role in its…
Abstract Number: 1805 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Complete Remission in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study in One Center
Jorge Romo-Tena¹, Diana Gómez-Martín¹, Roberto Reyna², Isaac Bartnicki-Navarrete³ and Jorge Alcocer-Varela¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by disease flares, alternated with periods of clinical remission. In the past years, the “treat-to-target” strategy in SLE…
Abstract Number: 1806 • 2016 ACR/ARHP Annual Meeting
Adherence to Treatment and Social, Educational Levels in Patients with Systemic Lupus Erythematosus
Raul Sueldo¹, Maria Constanza Bertolaccini², Ramiro Maldonado¹, Julia Romero³, Luciana Gonzalez Lucero⁴, Maximiliano Machado Escobar¹, Liliana Galindo⁵, Mirta Santana¹ and Eleonora Lucero¹, ¹Hospital Angel Cruz Padilla, Tucumán, Argentina, ²Rheumatology, Hospital Angel Cruz Padilla, Tucumán, Argentina, ³Rheumatology Service, Rheumatology Service, Hospital Británico, Buenos Aires, Buenos Aires, Argentina, ⁴Rheumatology Unit, Hospital Padilla, Tucumán, Tucumán, Argentina, ⁵Hospital Ángel Cruz Padilla, Tucuman, Argentina
Background/Purpose: To assess adherence to treatment in patients with Systemic Lupus Erythematosus (SLE) and to determine its relationship with social, educational levels and disease activity.…
Abstract Number: 1807 • 2016 ACR/ARHP Annual Meeting
Prevalence of Progressive Multifocal Leukoencephalopathy in Adults and Children with Systemic Lupus Erythematosus
Pooja Mahadeshwar¹, Teja Kapoor¹, Kayla Quinnies², Nicholas Tatonetti², Joyce Hui-Yuen³, Samantha Nguyen¹, Joan Bathon¹, Kayla Neville¹, James Miceli¹, Stacy Tanner⁴ and Anca Askanase¹, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Biomedical Informatics, Columbia University Medical Center, NY, NY, ³North Shore-Long Island Jewish Health System, Lake Success, NY, ⁴Rheumatology, Columbia University Medical Center, NY, NY
Background/Purpose: In the era of powerful immunosuppression, opportunistic infections are an increasing concern in Systemic Lupus Erythematosus (SLE). A potentially fatal opportunistic demyelinating disease of…
Abstract Number: 1808 • 2016 ACR/ARHP Annual Meeting
Frequency and Factors Associated with Thirty Day Hospital Readmissions Among Systemic Lupus Erythematosus Patients in a Community Hospital in the California Central Valley
Candice Yuvienco¹, Ololade Oladimeji², Ashenafi Legesse² and Paul Mills², ¹Internal Medicine, Division of Rheumatology, University of California San Francisco, Fresno Medical Education Program, Fresno, CA, ²Internal Medicine, University of California San Francisco, Fresno Medical Education Program, Fresno, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune condition which has one of the highest rates of hospital readmissions in the United States. There…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].